Updated time: 2023-02-17 15:45:46
12A-1011004
TW I495642、CN ZL201480007814.6、US 10214564 B2、US 10,752,657 B2
The rise of multidrug-resistant (MDR) pathogens causes an increasing challenge to public health. Recently, we identified a human hepatitis B virus (HBV)-derived polypeptide, which has a broad-spectrum antimicrobial activity at micro-molar concentrations, including some MDR- and colistin (polymyxin E)-resistant bacteria. This HBV peptide had no detectable cytotoxicity in various tissue culture systems and a mouse animal model. In the mouse model by inoculation with Staphylococcus aureus, timely treatment with this HBV peptide resulted in 100-fold reduction of bacteria load in blood, liver and spleen, as well as 100% protection of inoculated animals from death. Our current results suggested that this HBV peptide could be a new promising antimicrobial peptide (PLoS Pathogens, in press).
It can kill MDR-bacteria and colistin-resistant bacteria.
For treatment against Gram-positive and Gram-negative bacterial infection
Chiaho Shih, Heng-Li Chen, Pei-Yi Su
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Antimicrobial peptides derived from Hepatitis B virus